NCT02330380

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 26 (actual)
• Sponsor: University Hospitals Cleveland Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events. The final endpoint of the proposed study will be a ranking of the examined biomarkers based upon an integrated assessment of biomarker behavior over time. Secondary outcomes will assess changes in coronary artery calcification scoring, PET-MRI, skin biopsies, and clinical improvement.

Conditions

• Psoriasis
• Inflammation

Interventions

Type	Name	Description
DRUG	Methotrexate	Subjects will receive Methotrexate as detailed in the "Group" description.
DRUG	Ustekinumab	Subjects will receive Ustekinumab as detailed in the "Group" description.
DRUG	Etanercept	Subjects will receive Etanercept as detailed in the "Group" description.
DRUG	Adalimumab	Subjects will receive Adalimumab as detailed in the "Group" description.
DRUG	Acitretin	Subjects will receive Acitretin as detailed in the "Group" description.
OTHER	UVB Excimer Laser	Subjects will receive UVB Excimer Laser therapy as detailed in the "Group" description.
OTHER	Narrowband UVB	Subjects will receive Narrowband UVB as detailed in the "Group" description.

Timeline

• Start date: 2013-04-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2015-01-01
• Last updated: 2017-10-13

Locations

1 site across 1 country: United States